Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Appointed CFO
GILEAD SCIENCES, INC. (GILD) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 8-K Investor presentation
Docs: "Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 2 DRAFT Introduction • PD-1 inhibitor-based regimens have been established as the standard-of-care 1L treatment for mNSCLC,1,2 and novel combination therapies are needed to further improve outcomes • Sacituzumab govitecan is a Trop-2–directed ADC approved in the United States for the treatment of 2L+ mTNBC and pretreated HR+/HER2– mBC, and received accelerated approval for 2L mUC3 • Sacituzumab govitecan has previously demonstrated clinical activity and manageable safety in heavily pretreated patients with mNSCLC4 • EVOKE-02 is an ongoing, multicohort phase 2 study of sacituzumab govitecan + pembrolizumab ± platinum agent in patients with untreated 1L mNSCLC • Here, we report preliminary result..."
08/11/2023 4 Patterson Sandra (SVP, Controllership) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 1,306 shares @ $80, valued at $104.5k
Exercised 4,484 restricted stock units @ $0
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/04/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS"
07/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 SC 13D/A GILEAD SCIENCES, INC. reports a 35% stake in ARCUS BIOSCIENCES, INC.
06/30/2023 4 Lofton Kevin E (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 31 options to buy @ $0
06/30/2023 4 GILEAD SCIENCES, INC. (10% Owner) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Bought 1,010,000 shares @ $19.26, valued at $19.5M
06/28/2023 4 GILEAD SCIENCES, INC. (10% Owner) has filed a Form 4 on Allovir, Inc.
Txns: Bought 2,930,870 shares @ $3.75, valued at $11M
06/12/2023 4 Patterson Sandra (SVP, Controllership) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 153 shares @ $78.12, valued at $12k
Exercised 517 restricted stock units @ $0
06/12/2023 4 Parsey Merdad (Chief Medical Officer) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 1,294 shares @ $78.12, valued at $101.1k
Exercised 2,779 restricted stock units @ $0
06/12/2023 4 O'Day Daniel Patrick (Chairman & CEO) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 3,409 shares @ $78.12, valued at $266.3k
Exercised 7,346 restricted stock units @ $0
06/12/2023 4 Mercier Johanna (Chief Commercial Officer) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 1,272 shares @ $78.12, valued at $99.4k
Exercised 2,730 restricted stock units @ $0
06/12/2023 4 Dickinson Andrew D (CFO) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Paid exercise price by delivering 1,219 shares @ $78.12, valued at $95.2k
Exercised 2,618 restricted stock units @ $0
05/05/2023 8-K Quarterly results
05/04/2023 4 Kramer Kelly A. (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 restricted stock units @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 BARTON JACQUELINE K (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 Bluestone Jeffrey (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 restricted stock units @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 Horning Sandra (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 Lofton Kevin E (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 Rodriguez Javier (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 MANWANI HARISH (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Paid exercise price by delivering 368 shares @ $79.45, valued at $29.2k
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/04/2023 4 WELTERS ANTHONY (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 1,887 shares @ $0
Granted 10,173 options to buy @ $79.45, valued at $808.2k
05/02/2023 4 Lofton Kevin E (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Gifted 12,868 shares @ $0
04/27/2023 8-K Quarterly results
04/06/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/05/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
03/31/2023 4 Lofton Kevin E (Director) has filed a Form 4 on GILEAD SCIENCES, INC.
Txns: Granted 29 options to buy @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy